Loading stock data…
RCKT
$3.56+0.08 (+2.30%)
Market ClosedLast close May 1
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rocket Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.56. The stock is currently 57% below its 52-week high of $8.19, remaining 0.3% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why RCKT maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.56
Potential Upside
5%
Whystock Fair Value$3.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$8.84+148.3%
Range$3.00 – $16.00
Fundamentals
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$384.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-80.49%
Volume
Today's trading volume
1.83M
Recent News
Rocket to sell PRV for $180m to advance gene therapy pipeline
A PRV is issued by the FDA to sponsors whose products address certain rare paediatric diseases.
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is one of the penny stocks with the potential to rise 1000 percent. On March 27, Rocket Pharmaceuticals said the FDA approved KRESLADI for a rare pediatric disorder, giving the company its first marketed product and a key regulatory win after a long review path. The company said the approval also […]
Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy
Rocket Pharmaceuticals recently announced that the U.S. FDA has granted accelerated approval for KRESLADI (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) who lack a suitable HLA-matched sibling donor. The approval, which is supported by increased neutrophil CD18 and CD11a expression and includes a Rare Pediatric Disease Priority Review Voucher, underscores a significant regulatory...
Promising Penny Stocks To Consider In March 2026
Over the last 7 days, the U.S. market has dropped 1.6%, but it is up 15% over the past year, with earnings expected to grow by 16% annually in the coming years. In such a landscape, identifying stocks with strong financials and growth potential becomes crucial for investors seeking value beyond large-cap companies. Penny stocks—often smaller or newer firms—still offer compelling opportunities when backed by robust fundamentals, and this article highlights several that stand out as promising...